Prevention of neutrophil recruitment

A packaged pharmaceutical composition for treating a PMN responsive state in a subject, comprising:

• a container holding a therapeutically effective amount of at least one lipoxin compound having the formula
• wherein X is R1, OR1, or SR1;
• wherein R1 is
• (i) a hydrogen atom;
• (ii) an alkyl of 1 to 8 carbons atoms, inclusive, which may be straight chain or branched;
• (iii) a cycloalkyl of 3 to 10 carbon atoms;
• (iv) an aralkyl of 7 to 12 carbon atoms;
• (v) phenyl;
• (vi) substituted phenyl
• wherein Zi, Zii, Ziii, Ziv and Zv are each independently selected from —NO2, —CN, —C(═O)—R1, —SO3H, a hydrogen atom, halogen, methyl, —ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl;
• (vii) a detectable label molecule;
• or
• (viii) a straight or branched chain alkenyl of 2 to 8 carbon atoms, inclusive;
• wherein Q1 is (C═O), SO2 or (CN), provided when Q1 is CN, then X is absent;
• wherein Q3 and Q4 are each independently O, S or NH;
• wherein one of R2 and R3 is a hydrogen atom and the other is
• (a) H;
• (b) an alkyl of 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched;
• (c) a cycloalkyl of 3 to 6 carbon atoms, inclusive;
• (d) an alkenyl of 2 to 8 carbon atoms, inclusive, which may be straight chain or branched;
• or
• (e) RaQ2Rb wherein Q2 is —O— or —S—;
• wherein Ra is alkylene of 0 to 6 carbons atoms, inclusive, which may be straight chain or branched and wherein Rb is alkyl of 0 to 8 carbon atoms, inclusive, which may be straight chain or branched, provided when Rb is 0, then Rb is a hydrogen atom;
• wherein R4 is
• (a) H;
• (b) an alkyl of 1 to 6 carbon atoms, inclusive, which may be a straight chain or branched;
• wherein R5 is
• wherein Zi, Zii, Ziii, Ziv and Zv are each independently selected from —NO2, —CN, —C(═O)—R1, —SO3H, a hydrogen atom, halogen, methyl, —ORx, wherein Rx is 1 to 8 carbon atoms, inclusive, which may be a straight chain or branched, and hydroxyl or a substituted or unsubstituted, branched or unbranched alkyl group;
• wherein Y1 is —OH, methyl, —SH, an alkyl of 2 to 4 carbon atoms, inclusive, straight chain or branched, an alkoxy of 1 to 4 carbon atoms, inclusive, or CHaZb where a+b=3, a=0 to 3, b=0 to 3 and Z is cyano, nitro or a halogen;
• wherein R6 is
• (a) H;
• (b) an alkyl from 1 to 4 carbon atoms, inclusive, straight chain or branched;
• wherein T is O or S, and pharmaceutically acceptable salts thereof;
• and
• instructions for using said lipoxin compound for treating an PMN responsive state in the subject.